RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016
Summary
Global Markets Directs, RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016, provides in depth analysis on RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted pipeline therapeutics.
The report provides comprehensive information on the RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1)
- The report reviews RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Overview 7
Therapeutics Development 8
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Products under Development by Stage of Development 8
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Products under Development by Therapy Area 9
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Products under Development by Indication 10
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Products under Development by Companies 14
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23
ArQule, Inc. 23
AstraZeneca Plc 24
Cipher Pharmaceuticals Inc. 25
Merck & Co., Inc. 26
Novartis AG 28
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Drug Profiles 29
ARQ-092 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AZD-5363 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ISC-4 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
JRP-890 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MK-2206 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
MK-2206 + selumetinib sulfate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
uprosertib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Dormant Projects 43
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Featured News & Press Releases 46
Jan 28, 2016: ArQule Provides Update on ARQ 092 46
Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 46
Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 48
Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics 49
Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology 49
Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference 50
Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium 51
Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome 52
Oct 21, 2013: New Drug Combinations May Benefit Patients With Pancreatic Cancer 52
Apr 09, 2013: ArQules New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial 53
Apr 07, 2013: AstraZeneca's AKT Inhibitor AZD5363 Well Tolerated, Yieldes Partial Response In Patients With Advanced Solid Tumors, Phase I Study Finds 54
Nov 10, 2011: Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies Joint AKIP Research Collaboration 55
Apr 12, 2011: Astex Announces Commencement Of Phase I Study For AZD5363 In Anti-Cancer Collaboration With AstraZeneca 56
Jun 01, 2009: AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58
List Of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Products under Development by Companies, H1 2016 (Contd..2) 17
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by ArQule, Inc., H1 2016 23
Pipeline by AstraZeneca Plc, H1 2016 24
Pipeline by Cipher Pharmaceuticals Inc., H1 2016 25
Pipeline by Merck & Co., Inc., H1 2016 26
Pipeline by Novartis AG, H1 2016 28
Dormant Projects, H1 2016 43
Dormant Projects (Contd..1), H1 2016 44
Dormant Projects (Contd..2), H1 2016 45
List Of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 20
Number of Products by Stage and Routes of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
